Facilitated PCI: Rationale and design of the FINESSE trial

Journal of Invasive Cardiology

Volumn 13, Issue SUPPL. A, 2001, Pages

  Herrmann, Howard C ^a   Kelley, Michael P ^b   Ellis, Stephen G ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

HUMAN; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; FIBRINOLYTIC AGENTS; HUMANS;

EID: 0002704709     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Li RH, Herrmann HC. Facilitated percutaneous coronary intervention: A novel concept in expediting and improving acute myocardial infarction care. Am Heart J 2000;140(Suppl):1-8.
2. de Lemos JA, Antman EM, Gibson M, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: Observations from the TIMI 14 trial. Circulation 2000;101:239-243.
3. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695-2701.
4. Herrmann HC. Triple therapy for acute myocardial infarction: Combining fibrinolysis, platelet IIb/IIIa inhibition, and percutaneous coronary intervention. Am J Cardiol 2000;85:10C-16C.
5. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
6. Grines CL, Browne KF, Marco J, et al. for the PAMI Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-679.
7. Zijlstra F, Hoorntje JC, de Boer MJ, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999;341:1413-1419.
8. Gibbons RJ, Holmes DR Jr., Reeder GS, et al. for the Mayo Coronary Care Unit and Catheterization Laboratory Groups. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993;328:685-691.
9. The GUSTO IIb Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621-1628.
10. Ohman EM, Kleiman NS, Gacioch G, et al. for the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Circulation 1997;95:846-854.
11. Antman EM, Giugliano RP, Gibson M, et al. for the TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis. Circulation 1999;99:2720-2732.
12. The SPEED Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000;101:2794-2799.
13. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330;956-961.
14. Brener SJ, Barr LA, Burchenal JE, et al. for the RAPPORT Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734-741.
15. Montalscot G, Barragan P, Wittenberg O, et al. Abciximab associated with primary angioplasty and stenting in acute myocardial infarction: The ADMIRAL study, 30-day final results (Abstr). Circulation 1999;100(Suppl I):I-87.
16. Stone GW, Grines CL, Cox DA, et al. for the CADILLAC Investigators. A prospective, randomized trial comparing primary balloon angioplasty with or without abciximab to primary stenting with or without abciximab in acute myocardial infarction: Primary endpoint analysis from the CADILLAC trial. Presented at the American Heart Association. New Orleans, Louisiana, 2000.
17. Weaver W, Douglas MD, Simes R, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review. JAMA 1997;278:2093-2098.
18. Berger AK, Schulman KA, Gersh BJ, et al. Primary coronary angioplasty vs. thrombolysis for the management of acute myocardial infarction in elderly patients. JAMA 1999;282:341-348.
19. Grines CL, Cox DA, Stone GW, et al. for the STENT-PAMI Study Group. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 1999;341:1949-1956.
20. Suryapranata H, van't Hof AW, Hoomtje JC, et al. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation 1998;97:2502-2505.
21. Serruys PW, de Jaegere P, Kiemeneij F, et al. for the BENESTENT Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:496-501.
22. Fischman D, Leon M, Baim D, et al. for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
23. Rodriguez A, Bernardi V, Fernández M, et al. In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction (GRAMI trial). Am J Cardiol 1998;81:1286-1291.
24. Antoniucci D, Santoro GM, Bolognese L, et al. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: Results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol 1998;31:1234-1239.
25. Topol EJ, Mark DB, Lincoff M, et al. for the EPISTENT Investigators. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomized trial. Lancet 1999;354:2019-2024.
26. Lefkovitz J, Ivanhoe RJ, Califf RM, et al. for the EPIC Investigators. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996;77:1045-1051.
27. Neumann FJ, Zohlnhöfer D, Fakhoury L, et al. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999;34:1420-1426.
28. Schömig A, Kastrati A, Dirschinger J, et al. for the STOP-AMI Investigators. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 2000;343:385-391.
29. Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992;326:287-291.
30. Mauri F, Maggioni AP, Franzosi MG, et al. for the GISSI-2 Investigators. A simple electrocardiographic predictor of the outcome of patients with acute myocardial infarction treated with a thrombolytic agent: A GISSI-2 derived analysis. J Am Coll Cardiol 1994;24:600-607.
31. The TIMI Research Group. Immediate vs. delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. JAMA 1988;260:2849-2858.
32. Topol EJ, Califf RM, George BS, et al. for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581-588.
33. Simoons ML, Arnold AE, Betriu A, et al. for the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary intervention. Lancet 1998;1:197-203.
34. SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group. SWIFT trial of delayed elective intervention v. conservative treatment after thrombolysis with antistreplase in acute myocardial infarction. Br Med J 1991;302:555-560.
35. O'Neill WW, Weintraub R, Grines C, et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation 1992;86:1710-1717.
36. Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: The PACT trial. J Am Coll Cardiol 1999;34:1954-1962.
37. Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol 2000;36:1489-1496.
38. Brodie BR, Stuckey TD, Hansen A, Muncy D. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol 2000;85:13-18.